ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch

ABT.SW stock opened pre-market on 24 Feb 2026 at CHF86.50, down 13.50% from the previous close of CHF100.00 as traders reacted to weak session flow and sector rotation. This move places Abbott Laboratories (ABT.SW) on the Swiss SIX top losers list and tests the near-term support near the year low of CHF85.00. We look at valuation, technical signals, Meyka AI grading and model forecasts to explain the drop and what could re-anchor the share price in Swiss trading.

ABT.SW stock price action & market context

ABT.SW stock is trading on the SIX Switzerland market at CHF86.50 in pre-market trade on 24 Feb 2026, reflecting a -13.50% one-day move versus the previous close of CHF100.00. The share move is sharper than recent 50-day and 200-day averages (CHF95.35 and CHF101.01) and follows a wider healthcare sector pullback where large device makers underperformed. Year range stands at CHF85.00–CHF106.00, so current price is near the low end and likely to draw short-term technical interest.

Drivers: earnings calendar, company news and sector trends

Abbott has an upcoming earnings announcement scheduled for 2026-04-15 and no fresh public guidance today, which leaves the stock exposed to sector flows and macro headlines. Diagnostics and medical devices stocks have seen profit-taking after recent gains, and weaker market liquidity on SIX pre-market trading amplified the drop; recorded pre-market volume was 0 with an average volume flag of 1, so price moves can overshoot. For company background and product lines see Abbott’s investor site Abbott Laboratories.

Technicals and valuation for ABT.SW stock

Technicals show oversold momentum: RSI 14.95 and ADX 93.41 point to a strong trending move. MACD is negative at -2.12 (signal -0.70). Key support is the year low CHF85.00 and short-term resistance is the 50-day average CHF95.35. Valuation metrics: PE 30.77, EPS 2.86, market cap CHF153.02B, book value per share CHF29.31, and dividend yield near 2.20%. Those ratios mean the stock remains priced for growth, so downside often follows unexpected flow events.

Meyka AI rates ABT.SW with a score out of 100 and forecast

Meyka AI rates ABT.SW with a score of 74.40/100 (Grade B+, Suggestion: BUY). This grade factors S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Company-level third-party rating shows a C / Sell view dated 2026-02-23, highlighting mixed signals across ROE/ROA and DCF. Meyka AI’s forecast model projects a monthly target CHF87.30, a quarterly target CHF109.55, and a yearly target CHF100.56. Versus the current CHF86.50, the yearly forecast implies an upside of 16.26% while the quarterly target implies 26.64% upside. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.

Risks, catalysts and trading considerations

Near-term risks include low SIX pre-market liquidity, diagnostic cycle weakness, and earnings surprises on 2026-04-15; payout ratio is 61.99%, so dividend sustainability will remain monitored. Catalysts that could stabilise the share include better-than-expected diagnostics orders, device approvals, or stronger US reimbursement trends. Traders should note shares outstanding 1,738,871,947, free cash flow per share CHF3.95, and a debt-to-equity around 0.25, which provide balance-sheet support but do not immunise the stock from market-driven declines.

Analyst positioning and realistic price targets

Street coverage is mixed: internal companyRating data shows a C / Sell signal while some model-driven views favour recovery toward prior averages. Practical short-term targets: a defensive support trade near CHF85.00, a neutral recovery level at the 50-day CHF95.35, and a medium-term target aligned with Meyka AI at CHF100.56. For active investors we present a conservative stop near CHF83.00 and a risk-adjusted target range CHF95.00–CHF110.00, depending on upcoming earnings and sector momentum.

Final Thoughts

ABT.SW stock opened pre-market on 24 Feb 2026 at CHF86.50, down 13.50%, testing the year low support around CHF85.00. Technicals are oversold (RSI 14.95) and low pre-market liquidity can exaggerate moves on the SIX exchange. Meyka AI’s forecast model projects a yearly target of CHF100.56, implying +16.26% from the current price, while a nearer-term quarterly target sits at CHF109.55 for +26.64% upside. The company shows solid cash flow and a manageable debt profile, but mixed third-party ratings and a 61.99% payout ratio increase sensitivity to earnings misses. Investors should weigh the modelled upside against near-term volatility and upcoming earnings on 2026-04-15. Meyka AI provides this as data-driven market analysis; these forecasts and grades are model outputs, not guarantees or personal financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.